Lv1
18 积分 2024-04-22 加入
HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study
25天前
已完结
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
1个月前
已完结
Antibody–drug conjugates in lung and breast cancer: current evidence and future directions—a position statement from the ETOP IBCSG Partners Foundation
1个月前
已完结
Pertuzumab in the Treatment of HER2+Breast Cancer
1个月前
已完结
Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges
1个月前
已完结
Detailed curriculum vitae of HER2-targeted therapy
1个月前
已完结
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial
1个月前
已完结
Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non–Small Cell Lung Cancer: Implications for Precision Medicine
1个月前
已完结
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
1个月前
已完结
Tucatinib: First Approval
1个月前
已完结
皖公网安备34019202002308
